C.I. MedicalLtd (TSE:3540) Second Quarter 2024 Results
Key Financial Results
- Revenue: JP¥12.4b (up 11% from 2Q 2023).
- Net income: JP¥330.0m (down 53% from 2Q 2023).
- Profit margin: 2.7% (down from 6.3% in 2Q 2023). The decrease in margin was driven by higher expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
C.I. MedicalLtd Earnings Insights
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Healthcare industry in Japan.
Performance of the Japanese Healthcare industry.
The company's shares are up 29% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for C.I. MedicalLtd (2 don't sit too well with us!) that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:3540
C.I. MedicalLtd
Designs, manufactures, and sells dental care products in Japan.
Reasonable growth potential slight.